Innocrin Pharmaceuticals Overview

  • Founded
  • 2014
  • Status
  • Out of Business
  • Employees
  • 10
  • Latest Deal Type
  • Out of Business

Innocrin Pharmaceuticals General Information


Developer of oral inhibitors designed to treat breast and prostate cancer. The company's inhibitors help in treating castration-resistant prostate cancer and are used in other hormonally-driven conditions such as endometriosis or congenital adrenal hyperplasia, thereby enabling hospitals to treat even non-oncologic syndromes caused due to excessive androgen production.

Contact Information

Formerly Known As
Hephestics, Viamet Pharmaceuticals
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Therapeutic Devices
Medical Supplies
Primary Office
  • 4220 Appex Highway 55
  • Suite 330
  • Durham, NC 27713
  • United States
+1 (919) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Innocrin Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Oct-2019 000.00 Completed Out of Business
3. Later Stage VC 13-Jul-2017 000 000.00 Completed Generating Revenue
2. Later Stage VC 20-Apr-2015 $28.1M $28.1M Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view Innocrin Pharmaceuticals’s complete valuation and funding history, request access »

Innocrin Pharmaceuticals Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
Developer of oral inhibitors designed to treat breast and prostate cancer. The company's inhibitors help in treating cas
Drug Discovery
Durham, NC
10 As of 2016
00000000 00 000.00


et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut a
Gaithersburg, MD
00 As of 0000
0000 0000-00-00
00000000 00000


e velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
0000 000000000
Exton, PA
000 As of 0000
0000 0000-00-00
000000&0 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Innocrin Pharmaceuticals Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000000 Formerly VC-backed Exton, PA 000 0000 000000&0 0000
00000000000 000000 Accelerator/Incubator Backed New York, NY 000000000000
000000 00000000000 Formerly VC-backed San Diego, CA 00 00000 000000&0 00000
000000 00000000000 Private Equity-Backed Copenhagen, Denmark 0000 000000000000
You’re viewing 5 of 15 competitors. Get the full list »

Innocrin Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial